blast phase Chronic myeloid leukemia (DBCOND0023499)

Identifiers

Synonyms

Blast phase chronic myelogenic leukaemia / Blast phase chronic myologenic leukemia / Chronic Myelogenous Leukemia With Crisis of Blast Cells / Chronic Myelogenous Leukemia in Blast Crisis / Blastic Phase Chronic Myelogenous Leukemia / Blast-phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia (CML) in Blast Crisis / Blast phase Chronic myelocytic leukemia / Chronic Myelogenous Leukemia, Blastic Phase / Chronic Myeloid Leukemia, Blast Crisis / Blastic Phase Chronic Myeloid Leukemia / Blast Phase Chronic Myelogenous Leukemia (CML) / Blast phase Chronic myelogenous leukemia / Blast phase Chronic Myeloid Leukemia / Blastic phase chronic myeloid leukemia (disorder) / Blast cell crisis / Blast crisis (qualifier value) / Blast Crisis / Chronic myeloid leukaemia transformation

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Bosutinib	An antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments.	Tyrosine-protein kinase ABL1target Tyrosine-protein kinase Lyntarget Proto-oncogene tyrosine-protein kinase Srctarget ATP-dependent translocase ABCB1transporter Cytochrome P450 3A4enzyme Dual specificity mitogen-activated protein kinase kinase 1target Dual specificity mitogen-activated protein kinase kinase 2target Mitogen-activated protein kinase kinase kinase 2target Calcium/calmodulin-dependent protein kinase type II subunit gammatarget Cytochrome P450 2C8enzyme Tyrosine-protein kinase Fgrtarget Tyrosine-protein kinase HCKtarget Tyrosine-protein kinase Tectarget STE20-like serine/threonine-protein kinasetarget
Cytarabine	A pyrimidine nucleoside analogue used to treat acute non-lymphocytic leukemia, lymphocytic leukemia, and the blast phase of chronic myelocytic leukemia.	DNA polymerase betatarget Cytidine deaminaseenzyme Solute carrier family 22 member 4transporter ATP-binding cassette sub-family C member 10transporter Equilibrative nucleoside transporter 1transporter DNAtarget Cytochrome P450 3A4enzyme Deoxycytidine kinaseenzyme 5'-nucleotidaseenzyme Deoxycytidylate deaminaseenzyme DNA polymerase catalytic subunittarget
Dasatinib	A tyrosine kinase inhibitor used for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia.	Tyrosine-protein kinase ABL1target Tyrosine-protein kinase ABL2target Proto-oncogene tyrosine-protein kinase Srctarget Tyrosine-protein kinase Fyntarget Tyrosine-protein kinase Lcktarget Tyrosine-protein kinase Yestarget Mast/stem cell growth factor receptor Kittarget Platelet-derived growth factor receptor betatarget Ephrin type-A receptor 2target Signal transducer and activator of transcription 5Btarget Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 1A1enzyme Cytochrome P450 1A2enzyme Cytochrome P450 1B1enzyme Cytochrome P450 3A5enzyme Flavin-containing monooxygenase 3enzyme Tyrosine-protein kinase BTKtarget Nuclear receptor subfamily 4 group A member 3target Breakpoint cluster region proteintarget Tyrosine-protein kinase CSKtarget Ephrin type-A receptor 5target Ephrin type-B receptor 4target Tyrosine-protein kinase Fgrtarget Tyrosine-protein kinase FRKtarget Heat shock cognate 71 kDa proteintarget Tyrosine-protein kinase Lyntarget Mitogen-activated protein kinase kinase kinase 20target Mitogen-activated protein kinase 14target Amidophosphoribosyltransferasetarget
Imatinib	A tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.	Platelet-derived growth factor receptor betatarget Tyrosine-protein kinase ABL1target Mast/stem cell growth factor receptor Kittarget Proto-oncogene tyrosine-protein kinase receptor Rettarget High affinity nerve growth factor receptortarget Macrophage colony-stimulating factor 1 receptortarget Platelet-derived growth factor receptor alphatarget Epithelial discoidin domain-containing receptor 1target Cytochrome P450 3A4enzyme Breakpoint cluster region proteintarget Cytochrome P450 1A2enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Solute carrier family 22 member 1transporter ATP-dependent translocase ABCB1transporter Solute carrier family 22 member 2transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Phospholipid-transporting ATPase ABCA3transporter Albumincarrier Alpha-1-acid glycoprotein 1carrier Bile salt export pumptransporter Cytochrome P450 2C8enzyme ATP-binding cassette sub-family C member 2transporter Multidrug resistance-associated protein 1transporter Organic cation/carnitine transporter 2transporter Solute carrier organic anion transporter family member 1B3transporter ATP-binding cassette sub-family C member 4transporter Solute carrier organic anion transporter family member 1A2transporter Discoidin domain-containing receptor 2target Induced myeloid leukemia cell differentiation protein Mcl-1target
Ponatinib	A kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML).	Tyrosine-protein kinase ABL1target Breakpoint cluster region proteintarget Mast/stem cell growth factor receptor Kittarget Proto-oncogene tyrosine-protein kinase receptor Rettarget Angiopoietin-1 receptortarget Receptor-type tyrosine-protein kinase FLT3target Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2D6enzyme Cytochrome P450 3A5enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Fibroblast growth factor receptor 1target Fibroblast growth factor receptor 2target Fibroblast growth factor receptor 3target Fibroblast growth factor receptor 4target Tyrosine-protein kinase Lcktarget Proto-oncogene tyrosine-protein kinase Srctarget Tyrosine-protein kinase Lyntarget Vascular endothelial growth factor receptor 2target Platelet-derived growth factor receptor alphatarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01756118	A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia	Dactolisib	treatment	1	completed
NCT05794880	MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	No drug interventions	treatment	Not Available	recruiting
NCT03934372	Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors	Ponatinib	treatment	1 / 2	recruiting
NCT00111683	MK0457 in Patients With Leukemia (0457-003)	No drug interventions	treatment	1	completed
NCT01163201	T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies	Cyclophosphamide Fludarabine	treatment	1 / 2	withdrawn
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Beclomethasone dipropionate Methotrexate Tacrolimus	supportive_care	2	completed
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT04258943	Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia	Bosutinib	treatment	1 / 2	active_not_recruiting
NCT00316953	Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate	Dasatinib	treatment	1	completed
NCT00095797	XK469R in Treating Patients With Refractory Hematologic Cancer	No drug interventions	treatment	1	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT00101088	Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia	Imatinib Menthol Temsirolimus	treatment	1	terminated
NCT00933985	Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia	Dexrazoxane Doxorubicin Obatoclax Vincristine	treatment	1	terminated
NCT03647215	CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey	No drug interventions	Not Available	Not Available	completed
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT00006213	BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia	BMS-214662	treatment	1	completed
NCT01839916	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT00278330	Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia	Alvocidib Vorinostat	treatment	1	completed
NCT00098826	SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes	Ispinesib	treatment	1	completed
NCT00023920	Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia	Bevacizumab Cytarabine Idarubicin	treatment	2	terminated
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT00077467	Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia	Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT00459212	GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia	GTI-2040	treatment	1	completed
NCT00077181	3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies	Cytarabine Triapine	treatment	1	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT00540995	Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer	Beta-D-Glucose Busulfan Etoposide	treatment	1 / 2	terminated
NCT00098423	Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes	Cytarabine Tanespimycin	treatment	1	completed
NCT00702403	Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML	Imatinib Nilotinib	treatment	1 / 2	completed
NCT00005064	PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome	Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT01670084	Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia	Coenzyme M Cyclophosphamide Cytarabine Dexamethasone Doxorubicin Leucovorin Methotrexate Nilotinib Prednisone Rituximab Sulfate ion Vincristine	treatment	2	withdrawn
NCT01564277	Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies	Allopurinol Rasburicase	treatment	2	terminated
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Rituximab Tacrolimus	treatment	2	terminated
NCT00052598	Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant	Aldesleukin Therapeutic allogeneic lymphocytes	treatment	1 / 2	terminated
NCT00357305	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders	Cytarabine Etoposide Vorinostat	treatment	1	completed
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT00309907	Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant	Etanercept Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT00331513	Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes	Idarubicin Vorinostat	treatment	1	completed
NCT01231919	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	No drug interventions	treatment	1	completed
NCT00015834	STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia	Cytarabine Imatinib	treatment	1 / 2	completed
NCT00084916	CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase	Menthol Temsirolimus	treatment	2	completed
NCT00053963	FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia	Romidepsin	treatment	1	completed
NCT00387426	Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Sunitinib	treatment	2	terminated
NCT00860574	Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia	Fludarabine Methotrexate Tacrolimus Treosulfan	treatment	2	completed
NCT00101231	Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Alvocidib	treatment	1	terminated
NCT00054431	Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia	2'-Deoxycytidine Decitabine Imatinib	treatment	2	completed
NCT00012376	Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer	Bryostatin 1 Sargramostim	treatment	1	completed
NCT01849276	Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML	Cytarabine Metformin	treatment	1	terminated
NCT01053494	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer	No drug interventions	supportive_care	Not Available	completed
NCT00275080	Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	2'-Deoxycytidine Decitabine Vorinostat	treatment	1	completed
NCT01159301	Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia	Entinostat Sorafenib	treatment	1	terminated
NCT00087204	Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Becatecarin Rebeccamycin	treatment	1	completed
NCT00301769	SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia	SJG-136	treatment	1	terminated
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Busulfan Cyclophosphamide Cyclosporine Fludarabine	treatment	2	completed
NCT01056614	Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Fludarabine Methotrexate Tacrolimus	treatment	2	completed
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT00381550	3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia	Fludarabine Triapine	treatment	2	completed
NCT00301938	7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes	7-Hydroxystaurosporine Perifosine	treatment	1	completed
NCT00964873	A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia	Ganetespib	treatment	1	completed
NCT02091245	Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML	Selinexor	treatment	1	active_not_recruiting
NCT03842696	Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation	Cyclophosphamide Cyclosporine Methotrexate Mycophenolate mofetil Tacrolimus Vorinostat	prevention	1 / 2	recruiting
NCT00594555	A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia	Cladribine Cytarabine Filgrastim Imatinib	treatment	2	withdrawn
NCT02730312	PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies	Vibecotamab	treatment	1	completed
NCT01914484	Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia	Nilotinib Ruxolitinib	treatment	1 / 2	completed
NCT02782403	Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia	Axitinib Bosutinib	treatment	1	terminated